CD74 and intratumoral immune response in breast cancer
Open Access
- 6 April 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (8) , 12664-12674
Abstract
CD74 and intratumoral immune response in breast cancerKeywords
This publication has 46 references indexed in Scilit:
- CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent mannerOncotarget, 2015
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Annals of Oncology, 2015
- Triple-Negative Breast Cancer: Immune Modulation as the New Treatment ParadigmAmerican Society of Clinical Oncology Educational Book, 2015
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Annals of Oncology, 2014
- Role of Macrophage Migration Inhibitory Factor in the Regulatory T Cell Response of Tumor-Bearing MiceThe Journal of Immunology, 2012
- Importance of chemokine (CC-motif) ligand 2 in breast cancerThe International Journal of Biological Markers, 2012
- CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune diseaseExpert Opinion on Therapeutic Targets, 2011
- Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR)Breast Cancer: Basic and Clinical Research, 2011
- Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activityOncogene, 2007
- HLA‐DRB alleles are differentially expressed by tumor cells in breast carcinomaInternational Journal of Cancer, 2004